Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Identifieur interne : 002015 ( Main/Exploration ); précédent : 002014; suivant : 002016Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Auteurs : Jason Grebely [Australie] ; Stefan Mauss [Allemagne] ; Ashley Brown [Royaume-Uni] ; Jean-Pierre Bronowicki [France] ; Massimo Puoti [Italie] ; David Wyles [États-Unis] ; Macky Natha [États-Unis] ; Yanni Zhu [États-Unis] ; Junming Yang [États-Unis] ; Bruce Kreter [États-Unis] ; Diana M. Brainard [États-Unis] ; Chohee Yun [États-Unis] ; Val Carr [Royaume-Uni] ; Gregory J. Dore [Australie]Source :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antiviraux (usage thérapeutique), Association de médicaments (effets indésirables), Benzimidazoles (administration et posologie), Benzimidazoles (effets indésirables), Benzimidazoles (usage thérapeutique), Charge virale (), Femelle, Fluorènes (administration et posologie), Fluorènes (effets indésirables), Fluorènes (usage thérapeutique), Génotype, Hepacivirus (), Hepacivirus (génétique), Humains, Hépatite C chronique (génétique), Hépatite C chronique (sang), Hépatite C chronique (traitement médicamenteux), Interprétation statistique de données, Mâle, Ribavirine (administration et posologie), Ribavirine (effets indésirables), Ribavirine (usage thérapeutique), Réponse virologique soutenue, Sofosbuvir (administration et posologie), Sofosbuvir (effets indésirables), Sofosbuvir (usage thérapeutique), Test ELISA, Traitement de substitution aux opiacés, Usagers de drogues, Études rétrospectives.
- MESH :
- administration et posologie : Benzimidazoles, Fluorènes, Ribavirine, Sofosbuvir.
- effets indésirables : Association de médicaments, Benzimidazoles, Fluorènes, Ribavirine, Sofosbuvir.
- génétique : Hepacivirus, Hépatite C chronique.
- sang : Hépatite C chronique.
- traitement médicamenteux : Hépatite C chronique.
- usage thérapeutique : Antiviraux, Benzimidazoles, Fluorènes, Ribavirine, Sofosbuvir.
- Adulte, Adulte d'âge moyen, Charge virale, Femelle, Génotype, Hepacivirus, Humains, Interprétation statistique de données, Mâle, Réponse virologique soutenue, Test ELISA, Traitement de substitution aux opiacés, Usagers de drogues, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Antiviral Agents (therapeutic use), Benzimidazoles (administration & dosage), Benzimidazoles (adverse effects), Benzimidazoles (therapeutic use), Data Interpretation, Statistical, Drug Therapy, Combination (adverse effects), Drug Users, Enzyme-Linked Immunosorbent Assay, Female, Fluorenes (administration & dosage), Fluorenes (adverse effects), Fluorenes (therapeutic use), Genotype, Hepacivirus (drug effects), Hepacivirus (genetics), Hepatitis C, Chronic (blood), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (genetics), Humans, Male, Middle Aged, Opiate Substitution Treatment, Retrospective Studies, Ribavirin (administration & dosage), Ribavirin (adverse effects), Ribavirin (therapeutic use), Sofosbuvir (administration & dosage), Sofosbuvir (adverse effects), Sofosbuvir (therapeutic use), Sustained Virologic Response, Viral Load (drug effects).
- MESH :
- chemical , administration & dosage : Benzimidazoles, Fluorenes, Ribavirin, Sofosbuvir.
- chemical , adverse effects : Benzimidazoles, Fluorenes, Ribavirin, Sofosbuvir.
- chemical , therapeutic use : Antiviral Agents, Benzimidazoles, Fluorenes, Ribavirin, Sofosbuvir.
- adverse effects : Drug Therapy, Combination.
- blood : Hepatitis C, Chronic.
- drug effects : Hepacivirus, Viral Load.
- drug therapy : Hepatitis C, Chronic.
- genetics : Hepacivirus, Hepatitis C, Chronic.
- Adult, Data Interpretation, Statistical, Drug Users, Enzyme-Linked Immunosorbent Assay, Female, Genotype, Humans, Male, Middle Aged, Opiate Substitution Treatment, Retrospective Studies, Sustained Virologic Response.
Abstract
Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low. Our aim was to evaluate the impact of OST and drug use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledipasvir/sofosbuvir ± ribavirin.
DOI: 10.1093/cid/ciw580
PubMed: 27553375
Affiliations:
- Allemagne, Australie, France, Italie, Royaume-Uni, États-Unis
- Angleterre, Californie, District de Düsseldorf, Grand Est, Grand Londres, Lombardie, Lorraine (région), Nouvelle-Galles du Sud, Rhénanie-du-Nord-Westphalie
- Düsseldorf, Londres, Milan, Nancy, San Diego, Sydney, Vandœuvre-lès-Nancy
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001457
- to stream PubMed, to step Curation: 001435
- to stream PubMed, to step Checkpoint: 001435
- to stream Ncbi, to step Merge: 003A27
- to stream Ncbi, to step Curation: 003A27
- to stream Ncbi, to step Checkpoint: 003A27
- to stream Main, to step Merge: 002014
- to stream Main, to step Curation: 002015
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.</title><author><name sortKey="Grebely, Jason" sort="Grebely, Jason" uniqKey="Grebely J" first="Jason" last="Grebely">Jason Grebely</name><affiliation wicri:level="3"><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><wicri:orgArea>The Kirby Institute, UNSW Australia</wicri:orgArea></affiliation></author><author><name sortKey="Mauss, Stefan" sort="Mauss, Stefan" uniqKey="Mauss S" first="Stefan" last="Mauss">Stefan Mauss</name><affiliation wicri:level="3"><nlm:affiliation>Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for HIV and Hepatogastroenterology, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author><author><name sortKey="Brown, Ashley" sort="Brown, Ashley" uniqKey="Brown A" first="Ashley" last="Brown">Ashley Brown</name><affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Medicine, St Mary's Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Liver Unit, Department of Medicine, St Mary's Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U954, Universitary Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U954, Universitary Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region><settlement type="city">Vandœuvre-lès-Nancy</settlement><settlement type="city" wicri:auto="agglo">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name><affiliation wicri:level="3"><nlm:affiliation>Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Wyles, David" sort="Wyles, David" uniqKey="Wyles D" first="David" last="Wyles">David Wyles</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, University of California, San Diego.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Diego</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Infectious Diseases, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Natha, Macky" sort="Natha, Macky" uniqKey="Natha M" first="Macky" last="Natha">Macky Natha</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Yang, Junming" sort="Yang, Junming" uniqKey="Yang J" first="Junming" last="Yang">Junming Yang</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Kreter, Bruce" sort="Kreter, Bruce" uniqKey="Kreter B" first="Bruce" last="Kreter">Bruce Kreter</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Yun, Chohee" sort="Yun, Chohee" uniqKey="Yun C" first="Chohee" last="Yun">Chohee Yun</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Carr, Val" sort="Carr, Val" uniqKey="Carr V" first="Val" last="Carr">Val Carr</name><affiliation wicri:level="1"><nlm:affiliation>Gilead Sciences, Stockley Park, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Gilead Sciences, Stockley Park</wicri:regionArea><wicri:noRegion>Stockley Park</wicri:noRegion></affiliation></author><author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name><affiliation wicri:level="3"><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><wicri:orgArea>The Kirby Institute, UNSW Australia</wicri:orgArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27553375</idno><idno type="pmid">27553375</idno><idno type="doi">10.1093/cid/ciw580</idno><idno type="wicri:Area/PubMed/Corpus">001457</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001457</idno><idno type="wicri:Area/PubMed/Curation">001435</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001435</idno><idno type="wicri:Area/PubMed/Checkpoint">001435</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001435</idno><idno type="wicri:Area/Ncbi/Merge">003A27</idno><idno type="wicri:Area/Ncbi/Curation">003A27</idno><idno type="wicri:Area/Ncbi/Checkpoint">003A27</idno><idno type="wicri:Area/Main/Merge">002014</idno><idno type="wicri:Area/Main/Curation">002015</idno><idno type="wicri:Area/Main/Exploration">002015</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.</title><author><name sortKey="Grebely, Jason" sort="Grebely, Jason" uniqKey="Grebely J" first="Jason" last="Grebely">Jason Grebely</name><affiliation wicri:level="3"><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><wicri:orgArea>The Kirby Institute, UNSW Australia</wicri:orgArea></affiliation></author><author><name sortKey="Mauss, Stefan" sort="Mauss, Stefan" uniqKey="Mauss S" first="Stefan" last="Mauss">Stefan Mauss</name><affiliation wicri:level="3"><nlm:affiliation>Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for HIV and Hepatogastroenterology, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author><author><name sortKey="Brown, Ashley" sort="Brown, Ashley" uniqKey="Brown A" first="Ashley" last="Brown">Ashley Brown</name><affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Medicine, St Mary's Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Liver Unit, Department of Medicine, St Mary's Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U954, Universitary Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U954, Universitary Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region><settlement type="city">Vandœuvre-lès-Nancy</settlement><settlement type="city" wicri:auto="agglo">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name><affiliation wicri:level="3"><nlm:affiliation>Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Wyles, David" sort="Wyles, David" uniqKey="Wyles D" first="David" last="Wyles">David Wyles</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, University of California, San Diego.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Diego</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Infectious Diseases, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Natha, Macky" sort="Natha, Macky" uniqKey="Natha M" first="Macky" last="Natha">Macky Natha</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Yang, Junming" sort="Yang, Junming" uniqKey="Yang J" first="Junming" last="Yang">Junming Yang</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Kreter, Bruce" sort="Kreter, Bruce" uniqKey="Kreter B" first="Bruce" last="Kreter">Bruce Kreter</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Yun, Chohee" sort="Yun, Chohee" uniqKey="Yun C" first="Chohee" last="Yun">Chohee Yun</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Carr, Val" sort="Carr, Val" uniqKey="Carr V" first="Val" last="Carr">Val Carr</name><affiliation wicri:level="1"><nlm:affiliation>Gilead Sciences, Stockley Park, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Gilead Sciences, Stockley Park</wicri:regionArea><wicri:noRegion>Stockley Park</wicri:noRegion></affiliation></author><author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name><affiliation wicri:level="3"><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><wicri:orgArea>The Kirby Institute, UNSW Australia</wicri:orgArea></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (therapeutic use)</term><term>Benzimidazoles (administration & dosage)</term><term>Benzimidazoles (adverse effects)</term><term>Benzimidazoles (therapeutic use)</term><term>Data Interpretation, Statistical</term><term>Drug Therapy, Combination (adverse effects)</term><term>Drug Users</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Fluorenes (administration & dosage)</term><term>Fluorenes (adverse effects)</term><term>Fluorenes (therapeutic use)</term><term>Genotype</term><term>Hepacivirus (drug effects)</term><term>Hepacivirus (genetics)</term><term>Hepatitis C, Chronic (blood)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Hepatitis C, Chronic (genetics)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Opiate Substitution Treatment</term><term>Retrospective Studies</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (adverse effects)</term><term>Ribavirin (therapeutic use)</term><term>Sofosbuvir (administration & dosage)</term><term>Sofosbuvir (adverse effects)</term><term>Sofosbuvir (therapeutic use)</term><term>Sustained Virologic Response</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments (effets indésirables)</term><term>Benzimidazoles (administration et posologie)</term><term>Benzimidazoles (effets indésirables)</term><term>Benzimidazoles (usage thérapeutique)</term><term>Charge virale ()</term><term>Femelle</term><term>Fluorènes (administration et posologie)</term><term>Fluorènes (effets indésirables)</term><term>Fluorènes (usage thérapeutique)</term><term>Génotype</term><term>Hepacivirus ()</term><term>Hepacivirus (génétique)</term><term>Humains</term><term>Hépatite C chronique (génétique)</term><term>Hépatite C chronique (sang)</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Interprétation statistique de données</term><term>Mâle</term><term>Ribavirine (administration et posologie)</term><term>Ribavirine (effets indésirables)</term><term>Ribavirine (usage thérapeutique)</term><term>Réponse virologique soutenue</term><term>Sofosbuvir (administration et posologie)</term><term>Sofosbuvir (effets indésirables)</term><term>Sofosbuvir (usage thérapeutique)</term><term>Test ELISA</term><term>Traitement de substitution aux opiacés</term><term>Usagers de drogues</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Benzimidazoles</term><term>Fluorenes</term><term>Ribavirin</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benzimidazoles</term><term>Fluorenes</term><term>Ribavirin</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Benzimidazoles</term><term>Fluorenes</term><term>Ribavirin</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Benzimidazoles</term><term>Fluorènes</term><term>Ribavirine</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepacivirus</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Association de médicaments</term><term>Benzimidazoles</term><term>Fluorènes</term><term>Ribavirine</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hepacivirus</term><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Benzimidazoles</term><term>Fluorènes</term><term>Ribavirine</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Data Interpretation, Statistical</term><term>Drug Users</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Opiate Substitution Treatment</term><term>Retrospective Studies</term><term>Sustained Virologic Response</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Charge virale</term><term>Femelle</term><term>Génotype</term><term>Hepacivirus</term><term>Humains</term><term>Interprétation statistique de données</term><term>Mâle</term><term>Réponse virologique soutenue</term><term>Test ELISA</term><term>Traitement de substitution aux opiacés</term><term>Usagers de drogues</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"> Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low. Our aim was to evaluate the impact of OST and drug use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledipasvir/sofosbuvir ± ribavirin.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Californie</li><li>District de Düsseldorf</li><li>Grand Est</li><li>Grand Londres</li><li>Lombardie</li><li>Lorraine (région)</li><li>Nouvelle-Galles du Sud</li><li>Rhénanie-du-Nord-Westphalie</li></region><settlement><li>Düsseldorf</li><li>Londres</li><li>Milan</li><li>Nancy</li><li>San Diego</li><li>Sydney</li><li>Vandœuvre-lès-Nancy</li></settlement></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Grebely, Jason" sort="Grebely, Jason" uniqKey="Grebely J" first="Jason" last="Grebely">Jason Grebely</name></region><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name></country><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Mauss, Stefan" sort="Mauss, Stefan" uniqKey="Mauss S" first="Stefan" last="Mauss">Stefan Mauss</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brown, Ashley" sort="Brown, Ashley" uniqKey="Brown A" first="Ashley" last="Brown">Ashley Brown</name></region><name sortKey="Carr, Val" sort="Carr, Val" uniqKey="Carr V" first="Val" last="Carr">Val Carr</name></country><country name="France"><region name="Grand Est"><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name></region></country><country name="Italie"><region name="Lombardie"><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></region></country><country name="États-Unis"><region name="Californie"><name sortKey="Wyles, David" sort="Wyles, David" uniqKey="Wyles D" first="David" last="Wyles">David Wyles</name></region><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><name sortKey="Kreter, Bruce" sort="Kreter, Bruce" uniqKey="Kreter B" first="Bruce" last="Kreter">Bruce Kreter</name><name sortKey="Natha, Macky" sort="Natha, Macky" uniqKey="Natha M" first="Macky" last="Natha">Macky Natha</name><name sortKey="Yang, Junming" sort="Yang, Junming" uniqKey="Yang J" first="Junming" last="Yang">Junming Yang</name><name sortKey="Yun, Chohee" sort="Yun, Chohee" uniqKey="Yun C" first="Chohee" last="Yun">Chohee Yun</name><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002015 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002015 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27553375
|texte= Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27553375" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |